Welcome to our dedicated page for Urogen Pharma SEC filings (Ticker: URGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The UroGen Pharma Ltd. (URGN) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an Israel-organized biotechnology issuer listed on The Nasdaq Stock Market, UroGen submits periodic and current reports that describe its financial condition, oncology pipeline, and corporate governance.
Investors can review Forms 10-K and 10-Q for detailed discussions of UroGen’s business, including its RTGel® reverse-thermal hydrogel platform, approved products for low-grade upper tract urothelial cancer and recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, and revenue from product sales. These reports also outline research and development spending on programs such as UGN-103, UGN-104, and UGN-501, along with risk factors specific to urothelial and specialty cancer drug development.
Form 8-K filings provide timely updates on material events, such as quarterly financial results, executive compensation decisions, FDA approvals, and key commercialization milestones like the assignment of a permanent HCPCS Level II J Code (J9282) for ZUSDURI. Proxy materials on Schedule 14A describe annual meeting agendas, board elections, equity incentive plans, and advisory votes on executive pay and auditor engagement.
On Stock Titan, these filings are paired with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand complex oncology, financial, and governance disclosures. Users can also access information relevant to insider and equity-related activity through compensation and equity plan discussions referenced in UroGen’s 8-K and DEF 14A filings.
Barrett Elizabeth A. reported acquisition or exercise transactions in this Form 4 filing.
UroGen Pharma Ltd. reported that Chief Executive Officer Elizabeth A. Barrett received a grant of 153,195 restricted stock units on January 31, 2026. Each RSU represents the right to receive one ordinary share at no purchase price. One-third of the RSUs will vest on each of January 31, 2027, January 31, 2028, and January 31, 2029, aligning the CEO’s compensation with the company’s long-term performance.
The Toronto-Dominion Bank filed an amended Schedule 13G showing a passive ownership position in UroGen Pharma Ltd. as of 12/31/2025. The bank reports beneficial ownership of 2,302,334 ordinary shares, representing 4.9% of the outstanding class.
TD Bank has sole voting and dispositive power over all reported shares and no shared power. It certifies the shares were acquired and are held in the ordinary course of business, not to change or influence control of UroGen Pharma.
UroGen Pharma Ltd. General Counsel Jason Drew Smith reported equity award activity and related share sales. On January 31, 2026, multiple tranches of previously granted restricted stock units (RSUs) vested and were settled into ordinary shares, including awards originally granted in 2023, 2024, and 2025.
That same day, Smith received a new grant of 32,609 RSUs, which will vest in three equal installments on January 31, 2027, January 31, 2028, and January 31, 2029. On February 3, 2026, he sold ordinary shares at $19.69 per share to cover withholding tax obligations arising from the RSU settlements, and continued to hold tens of thousands of UroGen ordinary shares directly after these transactions.
UroGen Pharma Ltd.'s Chief Medical Officer, Mark Schoenberg, reported routine share sales linked to tax withholding on equity compensation. On February 3, 2026, he sold blocks of 1,844, 1,843, and 3,686 ordinary shares at
According to the filing, these shares were sold to satisfy withholding tax obligations arising from the settlement of restricted stock units. After these transactions, Schoenberg directly beneficially owned 144,985 ordinary shares of UroGen Pharma.
UroGen Pharma Ltd. Chief Medical Officer Mark Schoenberg reported equity compensation activity involving restricted stock units (RSUs) and ordinary shares. On January 31, 2026, previously granted RSUs converted into a total of 13,333 ordinary shares at an exercise price of $0, increasing his directly held ordinary shares.
On the same date, he received a new grant of 20,000 RSUs at $0. One-third of the shares underlying this new RSU award will vest on each of January 31, 2027, January 31, 2028, and January 31, 2029, providing staged future share delivery if vesting conditions are met.
UroGen Pharma Ltd. reported that its Chief Financial Officer, Chris Degnan, received a grant of restricted stock units on January 31, 2026. The award covers 32,609 RSUs, each representing a contingent right to receive one ordinary share of UroGen Pharma.
According to the grant terms, one-third of the shares underlying the RSUs will vest on each of January 31, 2027, January 31, 2028, and January 31, 2029, subject to the standard conditions. Following this grant, Degnan beneficially owns 32,609 derivative securities directly.
Mark Schoenberg filed a notice of proposed sale of restricted securities under Rule 144. The filing covers 13333 ordinary shares to be sold through Oppenheimer & Co. Inc., with an aggregate market value of 261460.13, on or about 02/02/2026 on the Nasdaq exchange.
The shares were acquired through restricted stock unit (RSU) grants from the issuer between 2023 and 2025. The notice also reports a prior sale of 10000 ordinary shares on 11/19/2025 for gross proceeds of 250005.00. By signing, the seller represents having no undisclosed material adverse information about the issuer.
UroGen Pharma Ltd. (URGN) reported an insider stock sale by its Chief Medical Officer. On 11/19/2025, the officer sold 10,000 ordinary shares in an open market transaction coded as a sale. The weighted average sale price was $25.00, with individual trades occurring between $25.00 and $25.02 per share.
The transaction was made under a pre-arranged Rule 10b5-1(c) trading plan that was adopted on 08/15/2025. After this sale, the officer directly beneficially owned 139,025 ordinary shares of UroGen Pharma.
UroGen Pharma Ltd. filed a Form S-8 to register additional ordinary shares for issuance under its 2017 Equity Incentive Plan. The filing uses General Instruction E to incorporate by reference prior effective S-8 registrations for the same plan. Exhibits include the Israeli legal opinion on share validity, auditor consent, plan documents, and the filing fee table.
UroGen Pharma (URGN) reported Q3 2025 results with revenue of $27,482 thousand, up from $25,204 thousand a year ago, as Jelmyto sales remained the primary driver and newly approved Zusduri contributed initial sales. Gross profit was $24,204 thousand. Operating expenses rose, led by selling, general and administrative costs of $37,582 thousand and research and development of $14,008 thousand, resulting in an operating loss of $27,386 thousand.
Net loss was $33,347 thousand (basic and diluted loss per share of $0.69). For the nine months, revenue reached $71,951 thousand with a net loss of $127,130 thousand. Cash, cash equivalents and marketable securities totaled $127.4 million as of September 30, 2025. The balance sheet reflected a prepaid forward obligation of $126,067 thousand and long‑term debt of $122,111 thousand. Shareholders’ deficit was $115,408 thousand.
Zusduri received FDA approval on June 12, 2025 and generated $1,779 thousand in Q3 sales, while Jelmyto delivered $25,703 thousand. Management stated that available cash and securities are expected to fund operations beyond one year from issuance. The company revised Q3 2024 loss per share to include 3,679,400 pre‑funded warrants in the weighted average shares outstanding.